DAFTAR PUSTAKA

American Psychiatric Association. 1994. ***Diagnostic and Statistical Manual of Mental Disorder***. 1994. American Psychiatric Association.

Anderson, R., Freedland, K., Clouse, R. and Lustman, P., 2001. The prevalence of comorbid depression in adults with diabetes a meta-analysis. ***Diabetes Care,*** Vol 24. pp. 1069 –1078.

Aronson, A. L., 1992. ***Recognition and Alleviation of Pain and Distress in Laboratory.*** Washington: The National Academy of Sciences.

Arozal, W. and Gunawan, S. G., 2009. Psikotropik. In: S. G. Gunawan, R. Setiabudy, N. and Elysabeth. (Eds.). ***Farmakologi dan Terapi.*** Jakarta: Balai Penerbit FKUI, p. 171.

Baldwin, D. S. and Birtwistle, J., 2002. ***An Atlas of Depression.*** Boca Raton: A CRC Press.

Barker, R. A., Barasi, S. and Neal, M. J., 1999. ***Neuroscience at a Glance.*** London: Blackwell Science Ltd.

Belzung, C. and Le pape, G. 1994. Comparison of Different Behavioral Test Situations used in psychopharmacology for measurement of anxiety. Physiology and Behavior, Vol.56 No.3, pp. 623-628.

Bendelow, G., 2009. ***Health, Emotion, and The Body.*** London: Polity Press.

Bergdahl, J. and Bergdahl, M., 2002. Perceived stres in adults: prevalence and association of depression, anxiety and medication in a Swedish population. ***Stres and Health,*** Vol.18 No.5, pp. 235–241.

Bleby, J. and Festing, M., 1974. The selection and supply of laboratory animals. In: C. Hume, (Eds.). ***The UFAW Handbook on the Care and Management of Laboratory Animals.*** p. 47.

Bourin, M., Colombel, M. C., Nizard, J., Redrobe, J. P., Nizard, J., Hascoet, M. and Baker, G. B., 1998. Evaluation of efficacies of different classes of antidepressants in the forced swimming test in mice at different ages. ***Prog. Neuro-Psychopharmacol. & Bid Psychiat,*** Vol 22, pp. 343-351.

Brismar, T., Maurex L., Cooray, G., Juntti-Berggren, L., Lindstrom, P., Ekberg, K., Adner, N. and Andersson, S., 2007. Predictors of cognitive impairment in type 1 diabetes. ***Psychoneuroendocrinology,*** Vol. 32 No.8–10, pp. 1041–1051.

Camara, A., Baldé, N. M., Enoru, S., Bangoura, J.S., Sobngwi, E. and Bonnet, F., 2014. Prevalence of anxiety and depression among diabetic African patients in Guinea: association with HbA1c levels. ***Diabetes & Metabolism,*** Vol. 7, pp. 1-7.

Chiodini, I., Adda, G., Scillitani, A., Coletti, F., Morelli, V., Lembo, S. D., Epaminonda, P., Masserini, B., Beck-Peccoz, P., Orsi, E., Ambrosi, B. and Arosio, M., 2007. Cortisol secretion in patients with type 2 diabetes. ***Diabetes Care,*** Vol. 30 No.1, p. 83–88.

Colcombe, S. J., Kramer, A. F., McAuley, E., Erickson, K. I. and Scalf, P., 2004. Neurocognitive aging and cardiovascular fitness: recent findings and future directions. ***Journal of Molecular Neuroscience,*** Vol. 24, pp. 9-14.

de Groot, M., Anderson, R., Freedland, K. E., Clouse, R. E. and Lustman, P. J., 2001. Association of depression and diabetes complications: a meta-analysis. ***Psychosomatic Medicine,*** Vol. 63 No. 4, pp. 619-630.

Dejgaard, A., Gade, A., Larsson, H., Balle, V., Parving, A. and Parving, H. H., 1991. Evidence for diabetic encephalopathy. ***Diabetic Medicine,*** Vol. 8 No. 2, pp. 162–167.

Funk, J. and Feingold, K., 1995. Disorder of the Endocrine Pancreas. In: S. J. McPhee, V. R. Lingappa, W. F. Ganong and J. D. Lange, (Eds.). ***Pathophysiology of Disease.*** San Fransisco: Appleton & Lange, p. 367-392.

Gehlawat, P., Gupta, R., Rajput, R., Gahlan, D., Virender., Gehlawat, K., 2013. Diabetes with comorbid depression: role of SSRI in better glycemic control. ***Asian Journal of Psychiatry,*** Vol. 6, pp. 364–368.

Gispen, W. H. and Biessels, G.-J., 2000. Cognition and synaptic plasticity in diabetes melitus. ***Trends Neuroscience,*** Vol. 23, pp. 542-549.

Graeff, F.G. and Rawlin, J. N. P. 1980. Dorsal periaqueductal gray punishment, septal lesions and the mode of action of minor tranquilizers. ***Pharmacology Biochemistry Behavior***, Vol 12, pp. 41-45.

Grahn, R., E., Kalman, B., A., Brennan, F., X., Watkins, L., R., Maier, S., F. 1994. The Elevated Plus-Maze is not sensitive to the effect of stressor controllability in rats. ***Pharmacology Biochemistry and Behavior***, Vol. 52 No. 3, pp. 565-570.

Guyton, A. C. eds. 1990. ***Fisiologi Manusia dan Mekanisme Penyakit.*** Diterjemahkan oleh Andrianto, P. Jakarta: EGC Penerbit Buku Kedokteran. pp 687-698.

Hadcock, S., Richardson, M. and Winocour, P. D., 1991. Intimal alterations in rabbit aortas during the first 6 months of alloxan-induced diabetes. ***Arteriosclerosis and Thrombosis,*** Vol. 11 No.2, pp. 517-530.

Hahn, D. B. and Payne, W. A., 2002. ***Focus on Health.*** 6th Ed. Mcgraw-Hill College.

Hascoet, M. and Bourin, M., 1998. A new approach to the light/dark test procedure in mice. ***Pharmacology Biochemistry and Behavior,*** Vol. 60 No. 3, pp. 645–653.

Ho, N., Sommers, M. S. and Luckl, I., 2014. Effect of diabetes on hipocampal neurogenesis: links to cognition and depression. ***Neuroscience and Biobehavioral Reviews,*** Vol 8, pp. 1-37.

Ikawati, Z., 2013. ***Farmakoterapi Penyakit Sistem Saraf Pusat***. Yogyakarta: Bursa Ilmu.

Kamei, J., Miyata, S., Morita, K., Saitoh, A. and Takeda, H., 2003. Effects of selective serotonin reuptake inhibitors on immobility time in the tail suspension test in streptozotocin-induced diabetic mice. ***Pharmacology, Biochemistry and Behavior,*** Vol 75, pp. 247–254.

Kamei, J., Miyata, S., Yamada, N., Hirano, S. and Tanaka, S., 2007. Diabetes attenuates psychological stress-elicited 5-HT secretion in the prefrontal cortex but not in the amygdala of mice. ***Brain Research,*** Volume 1147, pp. 233-239.

Kirkwood, C. K. and Melton, S. T., 2008. Anxiety disorder i: generalized anxiety, panic, and social anxiety disorders. In: J. T. Dipiro, R. L. Talbert, G. C. Yee, G. R. Matzke, B. G. Wells, L. M. Posey. (Eds.). ***Pharmacotherapy a Pathophysiologic Approach.*** New York: The McGraw-Hill Companies, pp. 1161-1176.

Kitaichi, Y., Inoue, T., Izumi, T., Nakagawa, S., Kato, A., Koyama, T., 2005. Subchronic milnacipran treatment increases basal extracellular noradrenaline consentrations in the medial prefrontal cortex of rats. ***European Journal of Pharmacology***. Vol.520, pp. 37-42.

Korte, S. M., De Boer, S.F., Bohus, B., 1999. Fear-potentiation in the elevated plus-maze test depends on stressor controllability and fear conditioning. ***Stress***, Vol.3 No.1, pp. 27-40.

Korte, S. M. and De Boer, S. F., 2003. A robust animal model of state anxiety: fear potentiated behaviour in the elevated plus maze. ***European Journal of Pharmacology***. Vol.463, pp. 163-175.

Lenzen, S., 2008. The mechanisms of alloxan- and streptozotocin-induced diabetes. ***Diabetologia,*** Vol.51, pp. 216–226.

Levine, S., 2005. Stress: an historical perspective. In: T. Steckler, N. Kalin and J. Reul, eds. ***Handbook of Stress and the Brain.*** San Diego: Elsevier, pp. 3-24.

Lu, F.-P., Lin, K.-P. and Kuo, H.-K., 2009. Diabetes and the risk of multi-system aging phenotypes: a systematic review and meta-analysis. ***DM and Geriatic Syndromes,*** Vol. 4 No. 1, pp. 1-10.

Lustman, P. J., Anderson, R. J., Freedland, K. E., de Groot, M., Carney, R. M., Clouse, R. M., 2000. Depression and poor glycemic control: a meta-analytic review of the literature. ***Diabetes Care,*** Vol. 23 No.7, pp. 934-942.

McCall, A., 1992. The impact of Diabetes on the CNS. ***Diabetes,*** Vol. 41, pp. 557-570.

Misslin, R., Belzung, C. and Vogel, E., 1989. Behavioural validation of a light/dark choice procedure for testing anti-anxiety agent. ***Behavioural Processes,*** Vol. 18, pp. 119-132.

Miyata, S., Shimoi, T., Hirano, S., Yamada, N., Hata, Y., Yoshikawa, N., Ohsawa, M. and Kamei, J., 2007. Effects of serotonergic anxiolytics on the freezing behavior in the elevated open-platform test in mice. ***Journal of Pharmacological Sciences,*** Vol. 272, pp. 272-278.

Mochizuki, D., Tsujita, Ryuichi., Yamada, Shinji., Kawasaki, K., Otsuka, Y., Hashimoto, S., Hattori, T., Kitamura, Y. and Miki, N., 2002. Neurochemical and behavioural characterization of milnacipran, a serotonin and noradrenaline reuptake inhibitor in rats. ***Psychopharmacology,*** Vol. 162, pp. 323-332.

Moojen, V. K. M., Martins, M. R., Reinke, A., Feier, G., Agostinho, F.R., Cechin, E. M., Quevedo, J., 2006. Effects of milnacipran in animal models of anxiety and memory. ***Neurochemistry Research***. Vol.31, pp. 571-577.

Pellow, S., Chopin, P., File, S. E., Briley, M. 1985. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. ***Journal of Neuroscience Methods***. Vol.14, pp. 149-167.

Potter, W. and Hollister, L., 2007. Antidepressant agent. In: B. Katzung, (Eds.). ***Basic & Clinical Pharmacology.*** New york: McGraw-Hill Companies, pp. 486-499.

Ramanathan, M., Jaiswal, A. K., 1998. Differential effects of diazepam on anxiety in streptozotocin induced diabetic and non-diabetic rats. ***Psychopharmacology***. Vol. 135, pp. 361-367.

Reagan, L. P., 2012. Diabetes as a chronic metabolic stressor: causes, consequences and clinical complication. ***Experimental Neurology,*** Vol. 233, pp. 68-78.

Rodgers, R. J. and Dalvi, A., 1997. Anxiety, defence and the elevated plus-maze. ***Neuroscience and Biobehavioral Reviews,*** Vol. 21 No. 6, pp. 801–810.

Rodgers, R. J. and Shepherd, J. K., 1993. Influence of prior maze experience on behaviour and response to diazepam in elevated plus maze and light/dark test of anxiety in mice. ***Psycopharmacology,*** Vol. 113, pp. 237-242.

Saitoh, A., Yamaguchi, K., Tatsumi, Y., Murusawa, H., Nakatani, A., Hirose, N., Yamada, M., Yamada, M., Kamei, J., 2007. Effect of milnacipran and fluvoxamine on hyperemotional behaviors and the loss of tryptophan hydroxylase-positive cells in olfactory bulbectomized rats. ***psycopharmacology***. Vol. 191, pp. 857-865.

Suherman, S., 2009. Insulin dan antidiabetik oral. In: S. G. Gunawan, R. Setiabudy, N. and Elysabeth, (Eds.). ***Farmakologi dan Terapi.*** Jakarta: Balai Penerbit FKUI, pp. 481-495.

Swiergiel, A. H., Leskov, I. L. and Dunna, A. J., 2008. Effects of Chronic and Acute Stressors and CRF on Depression-Like Behavior in Mice. ***Behavioural Brain Research,*** Vol. 186, pp. 32–40.

Syiem, D., Syngai, G., Khup, P. Z., Khongwir, B. S., Kharbuli, B. and Kayang, H., 2002. Hypoglycemic effects of Potentilla Fulgens L. in normal and alloxan-induced diabetes mice. ***Journal of Ethnopharmacology,*** Vol. 83, pp. 55-61.

Takeuchi, T., Owa, T., Nishino, T. and Kamei, C., 2010. Assessing anxiolytic-like effects of selective serotonin reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors using the elevated plus maze in mice. ***Methods and Finding in Experimental and Clinical Pharmacology,*** Vol. 32 No.2, pp. 113-121.

Teter, C. J., Kando, J. C., Wells, B. G. and Hayes, P. E., 2008. Depressive disorders. In: J. T. Dipiro, R. L. Talbert, G. C. Yee, G. R. Matzke, B. G. Wells, L. M. Posey. (Eds.). ***Pharmacotherapy a Pathophysiologic Approach.*** New York: The McGraw-Hill Companies, Inc., pp. 1123-1140.

Thorre, K., Chaouloff, F., Sarre, Meeusen, R., Ebinger, G., Michotte, Y. 1997. Differential effects of restraint stress on hipocampal 5-HT metabolism and extracellular levels of 5-HT in streptozotocin-in diabetic rats. ***Brain Research***. Vol 772, pp. 209-216.

Triplitt, C., Reasner, C. and Isley, W., 2008. Diabetes Mellitus. In: J. T. Dipiro, R. L. Talbert, G. C. Yee, G. R. Matzke, B. G. Wells, L. M. Posey. (Eds.). ***Pharmacotherapy A Pathophysiologic Approach.*** New York: The McGraw-Hill Companies, pp. 1205-1223.

Van Praag, H. M., 2004. Review article: Can stress cause depression?. ***Progress in Neuro-Psychopharmacology & Biological Psychiatry,*** Vol. 28, pp. 891– 907.

WHO, 2013. ***Screening for Type 2 Diabetes Report of a World Health Organization and International Diabetes Federation meeting***, Geneva: World Health Organization.

Zainuddin, M., 2011. ***Metodologi Penelitian.*** Surabaya: Airlangga University Press.